​​​​​​​​​South East London Area Prescribing Committee


This page is being updated until the content is moved to the SEL CCG website

The South East London Area Prescribing Committee (APC) was established in 2013 and is a partnership committee which discusses and makes recommendations on medicines issues.

Partner NHS organisations in South East London who are part of the APC are:

Bexley, Bromley, Greenwich, Lambeth, Lewisham and Southwark Clinical Commissioning Groups (CCGs),  Guys and St Thomas Foundation Trust, Kings College Hospital Foundation Trust,  South London and Maudsley Foundation Trust, Oxleas NHS Foundation Trust and Lewisham & Greenwich NHS Trust.

The committee also has representation from local Healthwatch organisations, NHS England London Area Team, and support from Medicines Information Services and the North East London Commissioning Support Unit.

Its aims are;

  • To provide a collective clinical leadership committee to ensure co-operation and consistency of approach to medicines optimisation across South East London
  • To enable all clinicians and commissioners to work together to ensure that patients have safe and consistent access to  medicines with the best outcomes
  • To advise on implementation of best practice around medicines, including National Institute for Health and Care Excellence ( NICE) guidelines and technology appraisals to encourage rapid and consistent implementation
  • To enable local NHS stakeholders and clinicians to exert a population approach to the prioritisation, improvement and quality of healthcare related to medicines.

The Medicines and Pathways Review Group is a working group of the APC which meets monthly to assess new medicines for prescribing within South East London, where these are intended to be prescribed in primary care or commissioned by Clinical Commissioning Groups.  Where primary care or commissioned medicines are subject to a new NICE technology appraisal, the APC will advise on best adoption and implementation in line with NICE. South East London wide treatment pathways and prescribing guidelines are also developed through the Committee and its sub-groups. 

The Local Trusts retain a Joint Formulary Committee which considers new drugs and changes of use of existing drugs which are used only within hospitals and are not subject to any specific commissioning arrangements.

If you are a South East London clinician and you wish to make an application for a new medicine to be considered by the APC please contact your local trust formulary pharmacist or, for primary care applications, your CCG medicines team.

Correspondence to the APC should be directed to:

T: 020 3049 4197

E: lamccg.medicinesoptimisation@nhs.net

Adalimumab - procurement and reference pricing FAQ.aspx
Adalimumab briefing October 2018.aspx
Biological medicines briefing for clinicians.aspx
Biological medicines next steps.aspx
Biologics best value briefing for specialist nurses.aspx
Biosimiar adalimumab briefing July 2018.aspx
Biosimilar adalimumab best value implementation plan.aspx
Biosimilar adalimumab briefing March 2018.aspx
Biosimilar adalimumab briefing May 2018.aspx
Biosimilar adalimumab homecare patient record.aspx
Biosimilar Adalimumab patient FAQs.aspx
Biosimilar adalimumab patient letter template.aspx
Biosimilar adalimumab toolkit .aspx
Biosimilar application to DTC.aspx
Biosimilar implementation group terms of reference.aspx
Biosimilars recommendations.aspx
Biosmilar savings tracker.aspx
Commissioning intentions adalimumab.aspx
Free of charge medicines scheme policy.aspx
Guidance on Homely Remedies.aspx
Insulin safety checklist template.aspx
London RMOC update July 2018.aspx
London update December 2018.aspx
Maintaining Patency of Central Venous Catheters in Adults.aspx
Midlands and East update April 2018.aspx
Midlands and East update September 2018.aspx
North update June 2018.aspx
North update November 2018.aspx
Position paper insulin safety.aspx
Position statement antidotes and rarely used medicines.aspx
Prescribing of Liothyronine.aspx
Principles guiding the decision making about the route of supply of medicines to outpatients - RMOC Guidance.aspx
Rarely Used and Urgent Medicines List.aspx
RMOC Advisory statement- Sequential Use of Biologic Medicines.aspx
RMOC briefing on adalimumab – July 2019.aspx
RMOC Freestyle Libre Position Statement.aspx
RMOC position statement on flash glucose monitoring.aspx
RMOC Position Statement-Oral vitamin B supplementation.aspx
Sodium oxybate in adult patients.aspx
South update November 2018.aspx
Standard Principles for Medicines Prior Approval Forms.aspx
Standardisation of TB products.aspx
STOMP catalogue of resources.aspx
STOMP local resources.aspx
STOMP summary paper.aspx
Updated RMOC Guidance – Prescribing of Liothyronine.aspx